Loading ...

Elisavet Serti

Immune Tolerance Network

Assessment Group

eserti@immunetolerance.org

Work:

Mobile:

Address:

Immune Tolerance Network

Committees:

,

Studies:

ITN017AI

-

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus

ITN018AI

-

Proleukin and Rapamune in Type 1 Diabetes

ITN027AI

-

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

ITN028AI

-

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

ITN041AI

-

A Research Trial of Aralast in New Onset Diabetes

ITN045AI

-

Inducing Remission in Type 1 Diabetes With Alefacept

ITN058AI

-

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

ITN065AI

-

TCZ in Pediatric New-onset T1D

ITN078AI

-

Immunotherapy to Preserve Residual Insulin in New-onset Type One Diabetes

ITN819AI

-

Type 1 Diabetes Immunotherapy Using Polyclonal Tregs

ITN825AI

-

Imatinib in New-onset T1D

ITN826AI

-

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D

ITN827AI

-

Tregs and IL-2 in Type 1 Diabetes

Bio:

Admin Links

Shortcuts

ITN Documents

Links